Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for InVivo Therapeutics Holdings Corp. (NVIV : NSDQ)

• Company Description    InVivo Therapeutics Holdings Corp. operates as a medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company intends to offer three products, including a biocompatible polymer scaffolding device to treat acute wound SCI; a biocompatible hydrogel for local controlled release of methylprednisolone to treat acute SCI; and a biocompatible polymer scaffolding device seeded with autologous hNSCs to treat acute and chronic SCI. InVivo Therapeutics Holdings Corp. is based in Cambridge, Massachusetts. Number of Employees: 6

• Price / Volume Information    Yesterday's Closing Price: $1.24 Daily Weekly Monthly 20 Day Moving Average: 18,992 shares Shares Outstanding: 3.11 (millions) Market Capitalization: $3.85 (millions) Beta: 0.83 52 Week High: $13.77 52 Week Low: $0.81 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.77% -10.30% 12 Week 8.77% 0.97% Year To Date -47.23% -52.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE KENDALL SQUARE SUITE B14402 - CAMBRIDGE,MA 02139 USA ph: 617-863-5500 fax: - info@invivotherapeutics.com http://www.invivotherapeutics.com

• General Corporate Information    Officers Richard Toselli - Chief Executive Officer;President C. Ann Merrifield - Chair of the Board Richard Christopher - Chief Financial Officer Heather Hamel - Chief Legal Officer and General Counsel Daniel R. Marshak - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 46186M605 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/22 Next Expected EPS Date: 06/06/23 Share - Related Items Shares Outstanding: 3.11 Most Recent Split Date: 4.00 (0.04:1) Beta: 0.83 Market Capitalization: $3.85 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 06/06/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.26 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -13.14% vs. Previous Quarter: -0.51% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/23 - -78.01 12/31/22 - -77.46 09/30/22 - -78.11 ROA 03/31/23 - -63.64 12/31/22 - -62.83 09/30/22 - -63.33 Current Ratio 03/31/23 - 8.85 12/31/22 - 7.13 09/30/22 - 4.62 Quick Ratio 03/31/23 - 8.85 12/31/22 - 7.13 09/30/22 - 4.62 Operating Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Net Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Pre-Tax Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Book Value 03/31/23 - 4.34 12/31/22 - 6.48 09/30/22 - 7.26 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00 Debt-to-Capital 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00

Powered by Zacks Investment Research ©